Viral O-GalNAc peptide epitopes: A novel potential target in viral envelope glycoproteins

Reviews in Medical Virology

Volumn 26, Issue 1, 2016, Pages 34-48

  Olofsson, Sigvard ^a   Blixt, Ola ^b   Bergström, Tomas ^a   Frank, Martin ^c   Wandall, Hans H ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BIOGNOS AB   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIGEN; EBOLA VACCINE; EPITOPE; GALACTOSYLTRANSFERASE; GLYCAN; GLYCOPEPTIDE; GLYCOSYLTRANSFERASE; HEPTAPEPTIDE; IMMUNOGLOBULIN G; MONOSACCHARIDE; MUCIN; N ACETYLGALACTOSAMINE; NEUTRALIZING ANTIBODY; OCTAPEPTIDE; OLIGOPEPTIDE; SUBUNIT VACCINE; SYNTHETIC PEPTIDE; VARICELLA ZOSTER VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

AMINO ACID SEQUENCE; ARTICLE; DRUG EFFICACY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; IMMUNOGENICITY; NONHUMAN; PHYLOGENY; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; SERODIAGNOSIS; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS MENINGITIS; VIRUS PARTICLE;

EID: 84954377399     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1859     Document Type: Article

References (80)

1. Zinkernagel RM, Hengartner H. Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunological Reviews 2006; 211: 310-319.
2. Dörner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity 2007; 27: 384-392.
3. Karlsson Hedestam GB, Fouchier RAM, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nature Reviews Microbiology 2008; 6: 143-155.
4. Hirsch RL. The complement system: its importance in the host response to viral infection. Microbiological Reviews 1982; 46: 71-85.
5. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clinical Infectious Diseases 2008; 47: 401-409.
6. Olofsson S, Hansen J. Host cell carbohydrate tagging of viral glycoproteins. A battlefield for the struggle between host defence and viral resistance mechanisms. Scandinavian Journal of Infectious Diseases 1998; 30: 435-440.
7. Markine-Goriaynoff N, Gillet L, Van Etten JL, Korres H, Verma N, Vanderplasschen A. Glycosyltransferases encoded by viruses. Journal of General Virology 2004; 85: 2741-2754.
8. Crispin M, Doores KJ. Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Current Opinion in Virology 2015; 11: 63-69.
9. Burton DR, Saphire EO, Parren PW. A model for neutralization of viruses based on antibody coating of the virion surface. Current Topics in Microbiology and Immunology 2001; 260: 109-143.
10. Burton DR, Williamson RA, Parren P. Antibody and virus: binding and neutralization. Virology 2000; 270: 1-3.
11. Schønning K, Lund O, Lund OS, Hansen JE. Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. Journal of Virology 1999; 73: 8364-8370.
12. Eisenberg RJ, Atanasiu D, Cairns TM, Gallagher JR, Krummenacher C, Cohen GH. Herpes virus fusion and entry: a story with many characters. Viruses 2012; 4: 800-832.
13. Olofsson S. Carbohydrates in herpesvirus infections. APMIS Supplementum 1992; 27: 84-95.
14. Burton DR. Antibodies, viruses and vaccines. Nature Reviews Immunology 2002; 2: 706-713.
15. Blixt O, Cló E, Nudelman AS, et al. A high-throughput O-glycopeptide discovery platform for seromic profiling. Journal of Proteome Research 2010; 9: 5250-5261.
16. Blixt O, Bueti D, Burford B, et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Research 2011; 13: R25.
17. Pedersen JW, Gentry-Maharaj A, Nøstdal A, et al. Cancer-associated autoantibodies to MUC1 and MUC4-a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. International Journal of Cancer 2014; 134: 2180-2188.
18. Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. International Journal of Cancer 2011; 128: 1860-1871.
19. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Research 2010; 70: 1306-1313.
20. Sørensen AL, Reis CA, Tarp MA, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006; 16: 96-107.
21. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nature Reviews Microbiology 2007; 5: 583-597.
22. Liljeqvist JA, Trybala E, Hoebeke J, Svennerholm B, Bergström T. Monoclonal antibodies and human sera directed to the secreted glycoprotein G of herpes simplex virus type 2 recognize type-specific antigenic determinants. Journal of General Virology 2002; 83: 157-165.
23. Ribeiro ACF, Ortona O, Simões SMN, et al. Binary mutual diffusion coefficients of aqueous solutions of sucrose, lactose, glucose, and fructose in the temperature range from (298.15 to 328.15) k. Journal of Chemical and Engineering Data 2006; 51: 1836-1840.
24. Cló E, Kracun SK, Nudelman AS, et al. Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis. Journal of Virology 2012; 86: 6268-6278.
25. Gillet L, Stevenson PG. Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B. EMBO Journal 2007; 26: 5131-5142.
26. D'Arrigo I, Cló E, Bergström T, Olofsson S, Blixt O. Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: diagnostic potential of O-glycopeptide microarrays. Glycoconjugate Journal 2013; 30: 633-640.
27. Serafini-Cessi F, Malagolini N, Dall'Olio F, Pereira L, Campadelli-Fiume G. Oligosaccharide chains of herpes simplex virus type 2 glycoprotein gG.2. Archives of Biochemistry and Biophysics 1985; 240: 866-876.
28. Olofsson S, Lundström M, Marsden H, Jeansson S, Vahlne A. Characterization of a herpes simplex virus type 2-specified glycoprotein with affinity for N-acetylgalactosamine-specific lectins and its identification as g92K or gG. Journal of General Virology 1986; 67(Pt 4): 737-744.
29. Corzana F, Busto JH, Jiménez-Osés G, et al. Serine versus threonine glycosylation: the methyl group causes a drastic alteration on the carbohydrate orientation and on the surrounding water shell. Journal of the American Chemical Society 2007; 129: 9458-9467.
30. Steentoft C, Vakhrushev SY, Joshi HJ, et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO Journal 2013; 32: 1478-1488.
31. Gill DJ, Clausen H, Bard F. Location, location, location: new insights into O-GalNAc protein glycosylation. Trends in Cell Biology 2011; 21: 149-158.
32. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 2012; 22: 736-756.
33. Wandall HH, Hassan H, Mirgorodskaya E, et al. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. Journal of Biological Chemistry 1997; 272: 23503-23514.
34. Mandel U, Hassan H, Therkildsen MH, et al. Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family. Glycobiology 1999; 9: 43-52.
35. Hagen Ten KG, Fritz TA, Tabak LA. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 2003; 13: 1R-16R.
36. Tian E, Hagen Ten KG. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconjugate Journal 2009; 26: 325-334.
37. Nordén R, Halim A, Nyström K, et al. O-linked glycosylation of the mucin domain of the herpes simplex virus type 1 specific glycoprotein gC-1 is temporally regulated in a seed-and-spread manner. Journal of Biological Chemistry 2015; 290: 5078-5091.
38. Tsurumi T, Fujita M, Kudoh A. Latent and lytic Epstein-Barr virus replication strategies. Reviews in Medical Virology 2005; 15: 3-15.
39. Chen M-R. Epstein-Barr virus, the immune system, and associated diseases. Frontiers in Microbiology 2011; 2: 5-5.
40. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Reviews in Medical Virology 2008; 18: 305-319.
41. Tabaa Al Y, Tuaillon E, Jeziorski E, et al. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis. Journal of Clinical Virology 2011; 52: 33-37.
42. Szakonyi G, Klein MG, Hannan JP, et al. Structure of the Epstein-Barr virus major envelope glycoprotein. Nature Structural and Molecular Biology 2006; 13: 996-1001.
43. Serafini-Cessi F, Malagolini N, Nanni M, et al. Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus. Virology 1989; 170: 1-10.
44. MacLennan IC, Casamayor-Palleja M, Toellner KM, Gulbranson-Judge A, Gordon J. Memory B-cell clones and the diversity of their members. Seminars in Immunology 1997; 9: 229-234.
45. Herrmann K, Frangou P, Middeldorp J, Niedobitek G. Epstein-Barr virus replication in tongue epithelial cells. Journal of General Virology 2002; 83: 2995-2998.
46. Frangou P, Buettner M, Niedobitek G. Epstein-Barr virus (EBV) infection in epithelial cells in vivo: rare detection of EBV replication in tongue mucosa but not in salivary glands. Journal of Infectious Diseases 2005; 191: 238-242.
47. Springer G. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198-1206.
48. Pinto R, Carvalho AS, Conze T, et al. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. Journal of Cellular and Molecular Medicine 2012; 16: 1474-1484.
49. Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochimica et Biophysica Acta 1780; 2008: 546-563.
50. Serafini-Cessi F, Dall'Olio F, Malagolini N, Campadelli-Fiume G. Temporal aspects of O-glycosylation of glycoprotein C from herpes simplex virus type-1. Biochemical Journal 1989; 262: 479-484.
51. Bagdonaite I, Nordén R, Joshi HJ, et al. A strategy for O-glycoproteomics of enveloped viruses-the O-glycoproteome of herpes simplex virus type 1. PLoS Pathogen 2015; 11: e1004784.
52. Spiro RG. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002; 12: 43R-56R.
53. Ju T. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proceedings of the National Academy of Sciences 2002; 99: 16613-16618.
54. Ju T, Cummings RD. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 2005; 437: 1252.
55. Radhakrishnan P, Dabelsteen S, Madsen FB, et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proceedings of the National Academy of Sciences of the United States of America 2014; 111: E4066-E4075.
56. Lundström M, Jeansson S, Olofsson S. Host cell-induced differences in the O-glycosylation of herpes simplex virus gC-1. II. Demonstration of cell-specific galactosyltransferase essential for formation of O-linked oligosaccharides. Virology 1987; 161: 395-402.
57. Ju T, Otto VI, Cummings RD. The Tn antigen-structural simplicity and biological complexity. Angewandte Chemie International Edition in English 2011; 50: 1770-1791.
58. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Computational Biology 2008; 4: e1000048.
59. Wang P, Sidney J, Kim Y, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010; 11: 568.
60. Nemazee D. Receptor selection in B and T lymphocytes. Annual Review of Immunology 2000; 18: 19-51.
61. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nature Reviews Immunology 2006; 6: 231-243.
62. Wertheim JO, Worobey M. Relaxed selection and the evolution of RNA virus mucin-like pathogenicity factors. Journal of Virology 2009; 83: 4690-4694.
63. Kracun SK, Cló E, Clausen H, Levery SB, Jensen KJ, Blixt O. Random glycopeptide bead libraries for seromic biomarker discovery. Journal of Proteome Research 2010; 9: 6705-6714.
64. Shaw AR. Human papillomavirus vaccines six years after approval. Annual Review of Medicine 2013; 64: 91-100.
65. Hansen JE, Nielsen C, Arendrup M, et al. Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. Journal of Virology 1991; 65: 6461-6467.
66. Steentoft C, Schjoldager KT, Cló E, et al. Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8). Glycoconjugate Journal 2010; 27: 571-582.
67. Thomsson E, Persson L, Grahn A, et al. Recombinant glycoprotein E produced in mammalian cells in large-scale as an antigen for varicella-zoster-virus serology. Journal of Virological Methods 2011; 175: 53-59.
68. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine 2015; 372: 2087-2096.
69. Botosso VF, de Zanotto PMA, Ueda M, et al. Positive selection results in frequent reversible amino acid replacements in the G protein gene of human respiratory syncytial virus. PLoS Pathogen 2009; 5: e1000254.
70. Mårdberg K, Nyström K, Tarp MA, et al. Basic amino acids as modulators of an O-linked glycosylation signal of the herpes simplex virus type 1 glycoprotein gC: functional roles in viral infectivity. Glycobiology 2004; 14: 571-581.
71. Luksza M, Lässig M. A predictive fitness model for influenza. Nature 2014; 507: 57-61.
72. Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. MBio 2014; 5: e00862-13.
73. Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. Journal of Infectious Diseases 2011; 204(Suppl 3): S825-S832.
74. Dowling W, Thompson E, Badger C, et al. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. Journal of Virology 2007; 81: 1821-1837.
75. Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000; 287: 1664-1666.
76. Blom N, Sicheritz-Pontén T, Gupta R, Gammeltoft S, Brunak S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 2004; 4: 1633-1649.
77. Yan A, Lennarz WJ. Unraveling the mechanism of protein N-glycosylation. Journal of Biological Chemistry 2005; 280: 3121-3124.
78. Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. Current Opinion in Structural Biology 2011; 21: 576-582.
79. Gawlitzek M, Estacio M, Fürch T, Kiss R. Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells. Biotechnology and Bioengineering 2009; 103: 1164-1175.
80. Jones J, Krag SS, Betenbaugh MJ. Controlling N-linked glycan site occupancy. Biochimica et Biophysica Acta 1726; 2005: 121-137.